Daniel Courchesne

Direktor/Vorstandsmitglied bei F3 Platform Biologics, Inc.

Finance

Consumer Services

Health Technology

Aktive Positionen von Daniel Courchesne

Unternehmen	Position	Beginn	Ende
F3 Platform Biologics, Inc. F3 Platform Biologics, Inc. BiotechnologyHealth Technology F3 Platform Biologics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel and practical biotechnology for human use. It handles research, clinical development, and commercialization of new indications surrounding amifostine, a compound that has been previously approved by FDA for indications involving the prevention and treatment of side effects related to cancer treatment and radiation therapy. The company was founded on June 5, 2018 and is headquartered in Atlanta, GA.	Direktor/Vorstandsmitglied	04.10.2019	-

Unternehmen	Position	Beginn	Ende
Global One Financial, Inc.	Präsident	-	-
ROYAL BANK OF CANADA	Corporate Officer/Principal	-	-
NATIONAL BANK OF CANADA	Corporate Officer/Principal	-	-
Entaire Global Cos., Inc. Entaire Global Cos., Inc. Finance/Rental/LeasingFinance Entaire Global Cos., Inc. provided funding and financing solutions. Its services included asset based lending, financial strategies, and solutions. The company was founded by Jonathan Rosen and William R. Muirhead in 2001 and was headquartered in Atlanta, GA.	Corporate Officer/Principal	01.06.2010	-

University of Sherbrooke

Undergraduate Degree

International

Vereinigte Staaten	4
Kanada	4

Operativ

Corporate Officer/Principal	3
Undergraduate Degree	1
Director/Board Member	1

Sektoral

Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Börsennotierte Unternehmen	2
ROYAL BANK OF CANADA	Finance
NATIONAL BANK OF CANADA	Finance

Private Unternehmen	3
Entaire Global Cos., Inc. Entaire Global Cos., Inc. Finance/Rental/LeasingFinance Entaire Global Cos., Inc. provided funding and financing solutions. Its services included asset based lending, financial strategies, and solutions. The company was founded by Jonathan Rosen and William R. Muirhead in 2001 and was headquartered in Atlanta, GA.	Finance
F3 Platform Biologics, Inc. F3 Platform Biologics, Inc. BiotechnologyHealth Technology F3 Platform Biologics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel and practical biotechnology for human use. It handles research, clinical development, and commercialization of new indications surrounding amifostine, a compound that has been previously approved by FDA for indications involving the prevention and treatment of side effects related to cancer treatment and radiation therapy. The company was founded on June 5, 2018 and is headquartered in Atlanta, GA.	Health Technology
Global One Financial, Inc.